Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy.
Saved in:
| Title: | Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy. |
|---|---|
| Authors: | Lutz R; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; Oncology Center Speyer, Speyer, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany., Grünschläger F; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Simon M; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany., Awwad MHS; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Bauer M; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-, Wittenberg, Germany., Yousefian S; Berlin Institute of Health (BIH) at Charité Universitätsmedizin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Charité Universitätsmedizin, Berlin, Germany., Beumer N; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.; Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany., Jopp-Saile L; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Sedlmeier A; Computational Oncology, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany., Solé-Boldo L; Berlin Institute of Health (BIH) at Charité Universitätsmedizin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Charité Universitätsmedizin, Berlin, Germany., Avanesyan B; Berlin Institute of Health (BIH) at Charité Universitätsmedizin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Charité Universitätsmedizin, Berlin, Germany., Vonficht D; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Stelmach P; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany., Steinbuss G; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Boch T; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany., Steiger S; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany., Baertsch MA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Prokoph N; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Rippe K; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany., Durie BGM; Cedars-Sinai Medical Center, Los Angeles, CA, USA., Wickenhauser C; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-, Wittenberg, Germany., Trumpp A; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany., Müller-Tidow C; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; Molecular Medicine Partnership Unit EMBL and University Hospital Heidelberg, Heidelberg, Germany., Hübschmann D; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Computational Oncology, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Innovation and Service Unit for Bioinformatics and Precision Medicine (BPM), German Cancer Research Center (DKFZ), Heidelberg, Germany., Weinhold N; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Raab MS; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Brors B; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany. b.brors@dkfz-heidelberg.de.; Medical Faculty and Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. b.brors@dkfz-heidelberg.de.; National Center for Tumor Diseases (NCT), Heidelberg, Germany. b.brors@dkfz-heidelberg.de.; German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany. b.brors@dkfz-heidelberg.de., Goldschmidt H; Department of Medicine V, Hematology, Oncology and Rheumatology, GMMG Studygroup, Heidelberg University Hospital, Heidelberg, Germany. hartmut.goldschmidt@med.uni-heidelberg.de., Imbusch CD; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany. c.imbusch@dkfz-heidelberg.de.; Institute of Immunology, University Medical Center Mainz, Mainz, Germany. c.imbusch@dkfz-heidelberg.de.; Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany. c.imbusch@dkfz-heidelberg.de.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany. c.imbusch@dkfz-heidelberg.de., Hundemer M; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany. michael.hundemer@med.uni-heidelberg.de., Haas S; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany. simon.haas@bih-charite.de.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany. simon.haas@bih-charite.de.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin, Berlin, Germany. simon.haas@bih-charite.de.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. simon.haas@bih-charite.de.; Charité Universitätsmedizin, Berlin, Germany. simon.haas@bih-charite.de.; Precision Healthcare University Research Institute, Queen Mary University of London, London, UK. simon.haas@bih-charite.de. |
| Source: | Nature communications [Nat Commun] 2024 Nov 29; Vol. 15 (1), pp. 10396. Date of Electronic Publication: 2024 Nov 29. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
